Mainz Biomed NV (MYNZ)
(Delayed Data from NSDQ)
$1.43 USD
-0.02 (-1.38%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $1.43 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MYNZ 1.43 -0.02(-1.38%)
Will MYNZ be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MYNZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MYNZ
Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates
Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates
MYNZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Anika Therapeutics (ANIK) Reports Q4 Loss, Tops Revenue Estimates
Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates
Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates
Other News for MYNZ
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and ...
12 Health Care Stocks Moving In Friday's Intraday Session
Mainz Biomed (MYNZ) Announces Sale of 1.47 Million Ordinary Units
Mainz Biomed files to sell 1.47M ordinary units
Mainz Biomed files to sell 1.47M ordinary units